1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia

BACKGROUND: Ceftazidime/avibactam (CAZ/AVI) may improve outcomes among patients with carbapenem-resistant Enterobacteriaceae (CRE) infections. However, the cost-effectiveness of CAZ/AVI is unknown. METHODS: We used a decision analytic model to estimate the health and economic consequences of CAZ/AVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Sfeir, Maroun, Satlin, Michael, Calfee, David P, Simon, Matthew S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254507/
http://dx.doi.org/10.1093/ofid/ofy210.1541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254507/
http://dx.doi.org/10.1093/ofid/ofy210.1541

Ejemplares similares